Sushruta Innovations and Wellness

What Sushruta Innovations and Wellness does

Sushruta Innovations and Wellness Pvt. Ltd. (operating as Sushruta Wellness) is an Indian private healthcare company that delivers autologous stem cell-based treatments to patients with orthopaedic, neurological, and autoimmune conditions. Founded in 2013 and headquartered in Kochi, the company operates three treatment centers in Vadodara, Bangalore, and Cochin, and positions itself as a pioneer of the Indian stem cell industry with over a decade of cumulative research and development.

The company's core offering is autologous stem cell therapy, in which cells are harvested from the patient's own body, processed in a GMP Class V certified sterile laboratory, and reinjected at the site of damage to promote regeneration. Treatment modalities include Adipose-Derived Stromal Vascular Fractions (SVF), Bone Marrow Mononucleate Cells, and Platelet Rich Plasma (PRP) therapy, delivered via local, intrathecal, or intravenous administration depending on the indication. The company claims 500+ patients treated across indications such as osteoarthritis, avascular necrosis, Parkinson's disease, multiple sclerosis, autism, cerebral palsy, juvenile diabetes, and muscular dystrophy.

The business model is direct-to-patient medical services, with revenue generated through per-treatment fees. Pricing is quote-based and determined after medical consultation, with no public disclosure of treatment costs. Patient acquisition is sales-led, relying on clinic visits, appointment booking via phone/email/website, and word-of-mouth driven by patient testimonials. The company is supported by investment from the Kerala State Industrial Development Corporation (KSIDC), a government-backed industrial development institution. Leadership consists of co-founders Dr. Nirupa Vyas (Managing Director) and Mr. Sandeep David (Director and CEO), and the team is reported at 1-10 employees.

Name

Sushruta Innovations and Wellness

Legal name

Sushruta Innovations and Wellness Pvt. Ltd.

Website

https://sushrutawellness.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Sushruta Innovations and Wellness is an Indian healthcare company that provides autologous stem cell therapy for orthopaedic, neurological, and autoimmune patients across three clinic locations in Vadodara, Bangalore, and Cochin.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

Keywords

• Regenerative medicine
• Stem cell therapy
• Autologous cell treatment
• Orthopaedic regenerative care
• Platelet rich plasma

Headquarters

HQ city

Kochi

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Treatment Services: Direct patient healthcare services providing autologous stem cell treatments, PRP therapy, and related medical procedures for orthopaedic, neurological, and autoimmune conditions. Revenue generated through treatment fees charged to patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Sushruta Innovations and Wellness is a healthcare center that provides autologous stem cell-based regenerative treatments for orthopaedic, neurological, and autoimmune conditions. Using cutting-edge modalities including stem cells, stromal vascular fractions (SVF), bone marrow mononucleate cells, and platelet rich plasma (PRP) therapy, the company harvests cells from each patient's own body, processes them in a GMP Class V certified laboratory, and reinjects them to regenerate damaged tissue. The company operates treatment centers in Vadodara, Bangalore, and Cochin, India.

Product overview

Sushruta Innovations and Wellness offers autologous stem cell-based treatments for a range of orthopaedic, neurological, and autoimmune conditions. The core offering is autologous stem cell treatment, supported by three specific treatment modalities: Adipose-Derived Stromal Vascular Fractions (ADSVFs), Platelet Rich Plasma (PRP) Therapy, and Bone Marrow Mononucleate Cells. These treatments are personalized using the patient's own cells, processed in their GMP Class V certified laboratory, and administered through various methods including local, intrathecal, and intravenous administration depending on the condition.

Differentiator

Problem solved

Functional benefit

Products and services

• Autologous Stem Cell Treatment

Quantifiable outcome

• Single stem cell treatment effective for 4-5 years in most cases
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Apollo Hospitals: India's largest hospital chain with a growing regenerative and cell therapy practice across multiple super-specialty centers. Comparable as an incumbent healthcare provider in India expanding into regenerative medicine, representing the dominant competitive threat Sushruta may face at scale.
• Medanta - The Medicity: Multi-specialty tertiary care provider in India operating advanced stem cell and bone marrow transplant programs. Comparable as a broad incumbent adding regenerative medicine capabilities, with materially larger clinical infrastructure than Sushruta.

Direct peers

• Advancells: India-based regenerative medicine provider offering autologous stem cell, PRP, and SVF therapies for orthopaedic, neurological, and chronic conditions via clinic-based delivery. Closely comparable in modality mix, treatment portfolio, and India-based clinical model to Sushruta.
• Stempeutics Research: Bangalore-based stem cell therapy company developing and commercializing stem cell-based products for orphan and lifestyle diseases. Directly comparable as an Indian stem cell therapeutics developer with multiple indications, GMP manufacturing capability, and similar regulatory positioning.
• LifeCell International: India-based stem cell banking and therapy company with autologous and family banking plus emerging cell therapy services. Comparable in autologous biological product model and India market focus, though commercially more mature and well-capitalized.
• ReGen Medisolutions (RMS): India-focused regenerative medicine clinic offering autologous bone-marrow-derived cell therapy for orthopedic and chronic conditions. Comparable in cell-processing service model, treatment indications, and direct-to-patient outpatient delivery.

Emerging players

• Global Stem Cell Group: Network of regenerative medicine clinics offering autologous stem cell and PRP treatments for orthopedic and autoimmune conditions. Comparable in autologous cell-therapy clinic model and orthopedic focus, although primarily US-based with international expansion.
• Dr. PRP America: US-based chain offering PRP and autologous biologics primarily for orthopedic and musculoskeletal indications. Comparable in PRP-centered autologous service model and outpatient clinic delivery, although operating in a different regulatory environment.
• Orthocell Limited: Australia-based regenerative medicine company developing autologous cell therapies for orthopedic and tendon repair indications. Comparable in autologous orthobiologic modality and orthopedic focus, but operating in a more mature regulatory environment (TGA).

Regional players

• Cryoviva (Cryobanks International): India and South-East Asia-focused stem cell banking company with adjacent therapeutic offerings. Comparable in GMP cell-processing capabilities and autologous biologics positioning across India, though core business skews to banking rather than therapy delivery.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/sushrutawellness
• LinkedInlinkedin.com/company/sushruta-wellness
• Instagraminstagram.com/sushrutawellness/

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sushruta Innovations and Wellness